United States· US:80491-7850_10e24e38-5645-433d-a160-82f4ed5b6dfb
QUVIVIQ
A daridorexant product containing daridorexant, registered in United States by Idorsia Pharmaceuticals Ltd. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Daridorexant is registered in 15 of 19 countries.
Countries holding a registration under ATC N05CJ03 (daridorexant), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Daridorexant · ATC N05CJ03
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of daridorexant costs, country by country.
Normalised to the WHO defined daily dose (50 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Daridorexant · price per daily dose (50 mg)
USD · FX 28 Sept 2026
- FR France$3.24
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DARIDOREXANT
- Manufacturer
- Idorsia Pharmaceuticals Ltd
- Country
- United States (US)
- ATC code
- N05CJ03
- ATC class
- Daridorexant
- Defined daily dose
- 50 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1180491785021 BLISTER PACK in 1 CARTON (80491-7850-2) / 7 TABLET, FILM COATED in 1 BLISTER PACK
- ndc1180491785031 BOTTLE in 1 CARTON (80491-7850-3) / 30 TABLET, FILM COATED in 1 BOTTLE
- ndc1180491-7850-2
- ndc1180491-7850-3
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Daridorexant in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaQUVIVIQIdorsia Pharmaceuticals Deutschland GmbH, Lörrach
- SwitzerlandQUVIVIQ 50 mg , FilmtablettenIdorsia Pharmaceuticals Ltd
- FinlandQUVIVIQIdorsia Pharmaceuticals Deutschland GmbH
- IrelandQUVIVIQ 50 mg film-coated tabletsIdorsia Pharmaceuticals Deutschland GmbH
- IcelandQuviviqIdorsia Pharmaceuticals Deutschland GmbH
- NetherlandsQuviviq 50 mg, filmomhulde tabletIdorsia Pharmaceuticals Deutschland GmbH
- PolandQUVIVIQIdorsia Pharmaceuticals Deutschland GmbH
- BelgiumQuviviq 50 mgIdorsia Pharmaceuticals Deutschland
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Quviviq
- Liechtenstein · Quviviq
- Norway · Quviviq
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0427632-a936-487c-8d9f-e13bc96e8607 GET /v1/drugs/c0427632-a936-487c-8d9f-e13bc96e8607?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "50",
"substance": "DARIDOREXANT",
"productndc": "80491-7850",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": "CIV",
"strength_unit": "mg/1",
"application_number": "NDA214985",
"marketing_category": "NDA"
}See everything about daridorexant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.